Impact Factor
Global reach, higher impact
Review Micro/nanorobotics for sepsis diagnosis and therapy: a frontier in precision medicine Full text PDF
Research Paper PEGylated IL2 and tumor-targeted radiotherapy augment CD8+ T cell-mediated anti-tumor response to anti-PD-1 in head and neck squamous cell carcinoma Full text PDF
Research Paper Targeting USP22 reprograms the tumor microenvironment and sensitizes KRAS/p53-driven lung cancer to anti-PD-1 immunotherapy Full text PDF
Research Paper Cardiomyocyte-Specific RNF128 Attenuates Pathological Cardiac Hypertrophy Progression by Stabilizing SERCA2a through Lys63-Linked Polyubiquitination Full text PDF
Research Paper Mapping endometrial vascular functional gradients using depth-derived ultrasound localization microscopy (D-ULM) for early stratification of postinjury fibrotic remodeling and therapeutic guidance Full text PDF
Research Paper Lactylation at H3K18 drives pathological angiogenesis via metabolic-epigenetic crosstalk in ischemic retinopathy Full text PDF
Issue 13; 2026
Founding Editor-in-Chief:
Prof. Xiaoyuan (Shawn) Chen, PhD
Profile
Theranostics publishes innovative research articles reflecting the fields of in vitro diagnostics and prognostics, in vivo molecular imaging, molecular therapeutics, image-guided therapy, biosensors, system biology and translational medicine, personalized medicine and a broad spectrum of biomedical research that can be applied to future theranostic applications.
- Theranostics is indexed by Science Citation Index (SCI) and MEDLINE. (Full index information)
- Full texts of articles in PubMed Central and Europe PMC. Abstracts in PubMed.
- (For NIH-funded researchers) Save time by submitting your paper to us - this journal is in full compliance with NIH Public Access Requirement.
Rationale: Ubiquitin-specific peptidase 22 (USP22), a deubiquitinase and component of the “Death-from-Cancer” 11-gene signature, is overexpressed in multiple malignancies and linked to recurrence, therapy resistance, and poor prognosis. Its role in KRAS/p53-driven lung cancer and the response to immune checkpoint inhibitors (ICIs) remains poorly defined. Here, we investigated USP22 as a potential therapeutic target in KRAS/p53-driven ...